|
August 3-5, 2009
(August 3-4 main conference)
寡聚核苷酸治疗是否成为单株抗体治疗的下一步?
在这个会议中，将针对寡聚核苷酸治疗是否会接续单株抗体治疗，形成广大流行之议题，进行广泛之讨论。口头发表主题包括寡聚核苷酸投递之机制及挑战、效力、毒性、以及各种形态寡聚核苷酸(siRNA, miRNA, antisense, aputama等)所带来之特殊性，此外，在展示目前各个阶段之药物研究的同时，探索寡聚核苷酸治疗成为药物发明中另一个新潮流的可能性。
Why You Should Attend:
- Meet Who's Who in the Oligonucleotide Industry
- Find out how leading minds of the industry are revolutionizing the industry with innovations in delivery, breakthroughs in understanding of mechanisms, efficacy and toxicity
- Hear the latest results of oligos in the clinic
Confirmed Speakers and Sessions
(As of March 16, 2009)
Here is Sneak Peak at the Agenda ...Confirmed Speakers and Sessions Include:
Keynote Address: RNAi Therapeutics - the Next Big Thing after Monoclonal Antibodies?
- Cy Stein, Professor, Urology & Molecular Pharmacology, Albert Einstein College of Medicine
Industry Keynote: 30 Years of Targeting RNA: A Retrospective
- Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation
Industry Leadership Forum: RNA Therapeutics - Are We Leveraging On The Promise?
- John Maraganore, Ph.D., Chief Executive Officer, Alnylam
- Klaus Giese, Ph.D., Chief Scientific Officer, Vice President, Research, Silence Therapeutics AG
- Paul Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.
- Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation
Delivery Challenges and Novel Delivery Systems
- Ian MacLachlan, Ph.D., Executive Vice President & Chief Scientific Officer, Tekmira Pharmaceuticals Corp.
- Gary R. Ostroff, Ph.D., Research Professor, University of Massachusetts Medical School
- Thomas Schluep, Ph.D., Chief Scientific Officer, Calando Pharmaceuticals
- Michael Templin, Ph.D., Discovery Research and Pharmaceutical Development, MDRNA Inc.
- Patrick Lu, Ph.D., President & CEO, Sirnaomics, Inc.
Specificity & Toxicity Considerations in Developing Oligonucleotide Therapeutics
- Satish Chandran, Ph.D., Chief Technology Officer, Pfizer RTC
- Richard S. Geary, Senior Vice President, Development, Isis Pharmaceuticals, Inc.
- Aimee Jackson, Ph.D., Director Drug Discovery, Regulus Therapeutics
Immunomodulation
- Dennis Klinman, Ph.D., M.D., Senior Investigator, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health
Preclinical & Clinical Development of siRNA, miRNA, Antisense and Aptamars
- Klaus Giese, Ph.D., CSO, VP Research, Silence Therapeutics
- James Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals, Inc.
- Dmitry Samarsky, Ph.D., Vice President, Technology Development, RXi Pharmaceuticals
- John Rossi, Ph.D., Professor & Chairman, Molecular Biology, Beckman Research Institute of The City of Hope, City of Hope Graduate School of Biological Sciences
- Francois Major, Ph.D., Professor, Computer Science, Institute for Research in Immunology and Cancer, Universite de Montreal
- William S. Marshall, Ph.D., President & CEO, Miragen Therapeutics
- Matt Winkler, Ph.D., Chief Executive Officer, Asuragen/Mirna Therapeutics
- Henrik Orum, Ph.D., Vice President & CSO, Santaris Pharma
- Mario Germano Giuliani, Ph.D., President & CEO, Giuliani SPA
- Kristin M. Thompson, Ph.D., Associate Director, Aptamer Discovery
Plus: an interactive Attendee/Speaker Chat Sessions that enables attendees to participate actively on topics including:
- Regulatory Updates - What's the Status, Relationship & Treatment of RNAi Compounds?
- Maximizing Therapeutic Oligo Manufacturing Efficiency via Customer and CMO Partnerships
- Delivery Innovations and Breakthroughs
- Current & Future Developments of miRNA
- RNAi for Target Validation
- Challenges and Limitations of In Vivo Models for Oligo Therapeutics
- Survey of the IP Landscape
Announcing "Rising TIDES - Development of Oligonucleotide Therapeutics in Japan", a post-conference workshop on Wednesday, August 5.
Find out what are the opportunities and challenges of developing oligonucleotide-based thereapeutics in Japan, and how you can enter the burgeoning market.
Scientific Advisory Board
Gary Carter, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc.
Aimee Jackson, Ph.D., Director Drug Discovery, Regulus Therapeutics
Troels Koch, Ph. D., Vice President Research, Santaris Pharma A/S
Dmitry Samarsky, Ph.D., VP, Technology Development, RXi Pharmaceuticals
James Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals
|
